The P144 topical cream, developed by ISDIN, targets skin fibrosis in patients with systemic sclerosis, a condition with significant unmet medical needs. The orphan drug designation by both the EMEA and FDA highlights the potential for market exclusivity and incentivizes further development. Given the prevalence of systemic sclerosis and the limited treatment options available, P144 could capture a substantial share of the market. Competitive analysis indicates that while there are existing therapies, none specifically target the TGF-beta pathway with a topical formulation, positioning P144 uniquely in the therapeutic landscape. Diligence implications suggest a need for robust safety and efficacy data to support market entry and reimbursement discussions.